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C
ardiovascular diseases are the most common cause of
death worldwide.
1 Atherosclerosis, the underlying
inﬂammatory disease, develops through the progressive accu-
mulationoflipidsandleukocytesinthevesselwall.Overthepast
30 years, lesional macrophages have emerged as central
inﬂammatory orchestrators of disease progression and its
complications. Macrophage precursors, the circulating mono-
cytes, invade predilection sites of dysfunctional endothelium,
differentiate, and engulf lipids. Lesional macrophages secrete
cytokines, chemokines, growth factors, and lytic enzymes that
promote plaque destabilization and rupture, which lead to
myocardial infarction and stroke. Interference with monocyte
recruitment and macrophage accumulation reduces lesion
burden in experimental models, which suggests that such
approachescouldbebeneﬁcialinhumandisease.
2–4
Much of current cardiovascular disease management
focuses on treatment of known risk factors such as high
cholesterol.3-Hydroxy-3-methylglutarylcoenzymeAreductase
inhibitors,theclassofdrugsknownasstatins,lowercholesterol
but also can exert atheroprotection by targeting inﬂamma-
tion.
5,6 Treatment of atherothrombotic disease by direct and
speciﬁc targeting of inﬂammation is being investigated,
7 and
clinicaltrialswithlow-dosemethotrexate
8andanti–interleukin-
1b
9areunderway.Althoughthesestudiesareexciting,previous
work reminds us that antiinﬂammatory approaches require
caution. Indiscriminate blockade of CD40L showed promise in
several experimental studies, but clinical trials had to be
aborted because of thromboembolic complications. More
selective inhibition of the interaction of CD40L with integrin
Mac-1, however, impaired atherogenesis without affecting
thrombus formation.
10 The example illustrates that strategies
aimed at targeting inﬂammation should be considered in their
immunophysiological and molecular contexts.
In this issue of the Journal of the American Heart
Association, Furusho et al
11 endeavor to treat atherosclerosis
by targeting and killing lesional macrophages with an
anti–folate receptor b (FRb) immunotoxin. Macrophages
upregulate FRb during inﬂammation.
12 Peritoneal murine
macrophages, for example, upregulate FRb in response to
challenge with thioglycollate, zymosan, or bacteria,
13 and
macrophages in rheumatoid arthritis and pulmonary ﬁbrosis
express functionally active FRb that can be targeted thera-
peutically in an experimental setting.
14–17 The idea for the
study by Furusho et al was therefore simple. If lesional
FRb-expressing macrophages are atherogenic, then delivery
of a recombinant immunotoxin (a truncated Pseudomonas
exotoxin A [PE38] conjugate that kills the infected cell) to
those macrophages should be atheroprotective. The anti-FRb
immunotoxin was meant to achieve 3 aims: to target
FRb-expressing cells, to facilitate internalization of the toxin
in those cells, and, by implication, to minimize adverse effects
of the toxin on bystander, non–FRb-expressing cells.
Although others have shown in animal models that lesional
macrophages upregulate the folate receptor,
18,19 Furusho et al
are the ﬁrst to target increased FRb expression on lesional
macrophages therapeutically. The authors provide evidence
by immunohistochemistry and immunoﬂuorescence that FRb
is expressed by 60% to 70% of CD68-positive lesional
macrophages but not by T cells, endothelial cells, or smooth
muscle cells. The authors report on FRb expression in human
carotid artery plaques and show that treatment of mice with
anti-FRb immunotoxin decreased lesional macrophage con-
tent compared to controls. This reduction in cell number was
associated with a reduction in percent lesion area. Impor-
tantly, differential blood cell counts did not change in the anti-
FRb immunotoxin group, which suggests a mechanism that is
localized and presumably limited to the plaque. Indeed, the
authors reported increased cell death in lesions, lending
further support that the anti-FRb immunotoxin acted locally.
Is the study convincing? The effects of the immunotoxin on
CD68-positive macrophages are striking, but it is not yet
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EDITORIALentirely clear how the immunotoxin achieves this. The TUNEL
(terminal deoxynucleotidyl transferase dUTP nick end labeling)
staining is a clue that the immunotoxin speciﬁcally triggers
cell death, but no colocalization of TUNEL-positive and FRb-
expressing cells is shown. Moreover, a precise phenotypic
analysis of FRb-expressing cells in atherosclerotic lesions is
lacking, and the observation that CD68-positive cells colocal-
ize with FRb does not preclude the possibility that other
important cells are affected.
Despite some uncertainties, the phenotype described in
this work is compelling and warrants further work. It remains
to be determined whether FRb-expressing macrophages
represent a distinct subset of lesional macrophages or an
activation state, as well as whether these macrophages are
functionally distinct from their FRb-negative counterparts. As
the authors mention, induction of macrophage apoptosis in
atherosclerotic lesions could be a double-edged sword.
Although beneﬁcial in early stages of lesion formation, the
increased cell death at more advanced stages might be
detrimental.
20 It is also worth considering that folic acid and
folate, also known as vitamin B9, are important to many
biological functions, such as DNA synthesis and repair.
Elimination of cells expressing a particular receptor could
have other unforeseen effects that counterbalance the
potential beneﬁts observed in this study. Nevertheless, the
authors have engineered a clever method to target a
formidable cell (Figure 1). The Greek metaphor, though
imperfect, can be illustrative: If the macrophage is Achilles
and the folate receptor is his Heel, then the antibody is Paris’
arrow and the exotoxin the poison that ultimately kills the
greatest warrior of the Trojan War.
Source of Funding
Dr Swirski is supported in part by NIH 1R01HL095612. Dr
Hilgendorf is supported by the German Research Foundation.
Disclosures
None.
References
1. World Health Organization. Global status report of noncommunicable disease;
2010. Available at: http://www.who.int/nmh/publications/ncd_report_full_
en.pdf. Accessed July 14, 2012.
2. Stoneman V, Braganza D, Figg N, Mercer J, Lang R, Goddard M, Bennett M.
Monocyte/macrophage suppression in CD11b diphtheria toxin receptor
transgenic mice differentially affects atherogenesis and established plaques.
Circ Res. 2007;100:884–893.
3. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J,
Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ. Monocyte subsets
differentially employ CCR2, CCR5, and CX3CR1 to accumulate within
atherosclerotic plaques. J Clin Invest. 2007;117:185–194.
4. Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G,
Lee KM, Kim JI, Markmann JF, Marinelli B, Panizzi P, Lee WW, Iwamoto Y,
Milstein S, Epstein-Barash H, Cantley W, Wong J, Cortez-Retamozo V, Newton
A, Love K, Libby P, Pittet MJ, Swirski FK, Koteliansky V, Langer R, Weissleder R,
Anderson DG, Nahrendorf M. Therapeutic siRNA silencing in inﬂammatory
monocytes in mice. Nat Biotechnol. 2011;29:1005–1010.
5. Zhou Q, Liao JK. Pleiotropic effects of statins: basic research and clinical
perspectives. Circ J. 2010;74:818–826.
6. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AMJ, Kastelein JJ, Koenig
W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J,
Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and
women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
7. Charo IF, Taub R. Anti-inﬂammatory therapeutics for the treatment of
atherosclerosis. Nat Rev Drug Discov. 2011;10:365–376.
8. Ridker PM. Testing the inﬂammatory hypothesis of atherothrombosis:
scientiﬁc rationale for the cardiovascular inﬂammation reduction trial (CIRT).
J Thromb Haemost. 2009;7(suppl 1):332–339.
9. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the
prevention of recurrent cardiovascular events: rationale and design of the
Canakinumab Anti-inﬂammatory Thrombosis Outcomes Study (CANTOS). Am
Heart J. 2011;162:597–605.
10. Wolf D, Hohmann JD, Wiedemann A, Bledzka K, Blankenbach H, Marchini T,
Gutte K, Zeschky K, Bassler N, Hoppe N, Rodriguez AO, Herr N, Hilgendorf I,
Stachon P, Willecke F, Duerschmied D, von zur Muhlen C, Soloviev DA, Zhang
L, Bode C, Plow EF, Libby P, Peter K, Zirlik A. Binding of CD40L to Mac-1’s
I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment
and atherosclerosis—but does not affect immunity and thrombosis in mice.
Circ Res. 2011;109:1269–1279.
11. Furusho Y, Miyata M, Matsuyama T, Nagai T, Li H, Akasaki Y, Hamada N,
Miyauchi T, Ikeda Y, Shirasawa T, Ide K, Tei C. Novel therapy for
atherosclerosis using recombinant immunotoxin against folate receptor b–
expressing makrophages. J Am Heart Assoc. 2012;1:e003079. doi:10.1161/
JAHA.112.003079
Figure 1. Proposed model of immunotoxin-mediated killing of FRb-expressing macrophages in atherosclerotic lesions. The immunotoxin
consists of a recombinant, biologically active fragment of Pseudomonas exotoxin A (PE38) that is linked to the disulﬁde-stabilized variable region
fragment (dsFv) of a monoclonal antibody (mab) against FRb. Upon binding to FRb on lesional macrophages, the immunotoxin is internalized and
intracellularly processed, leading to toxin-mediated adenosine triphosphate–ribosylation and inactivation of elongation factor 2, inhibition of
protein synthesis, and cell death. Elimination of FRb-positive macrophages reduces atherosclerosis. VL indicates variable region of the light chain;
VH, variable region of the heavy chain; and FRb, anti–folate receptor b.
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